Возможности иммунотерапии рака предстательной железы

Возможности иммунотерапии рака предстательной железы

Автор: Ощепков В.Н., Сивков А.В., Гарманова Т.Н.

Журнал: Экспериментальная и клиническая урология @ecuro

Рубрика: Онкоурология

Статья в выпуске: 4, 2011 года.

Бесплатный доступ

Рак простаты, вакцина от рака простаты, противоопухолевая вакцинация, пса, рар, дендритофаг-rpsa, псма

Короткий адрес: https://sciup.org/142188277

IDR: 142188277

Список литературы Возможности иммунотерапии рака предстательной железы

  • Kantoff PW, Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F., Redfern C.H., Ferrari A.C., Dreicer R., Sims R.B., Xu Y., Frohlich M.W, Schellhammer P.F.; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer//N. Engl. J. Med., 2010, Vol. 363, № 5. P. 411-422.
  • Jones G.W., Mettlin C., Murphy G.P., Guinan P., Herr H.W., Hussey D.H., Chmiel J.S., Fremgen A.M., Clive R.E., Zuber-Ocwieja K.E. Patterns of care for carcinoma of the prostate gland;results of a national survey of 1984 and 1990//J. Am. Coll. Surg. 1995. Vol. 180, № 5. P. 545-554.
  • Hanks G.E., Krall J.M., Hanlon A.L., Asbell S.O., Pilepich M.V., Owen J.B. Patterns of care and RTOG studies in prostate cancer: long-term survival, hazard rate observations, and possibilities of cure//Int. J. Radiat. Oncol. Biol. Phys. 1994. Vol.28, № 1. P. 39-45.
  • Middleton R.G., Smith J.A.Jr., Melzer R.B., Hamilton P.E. Patient survival and local recurrence rate following radical prostatectomy for prostatic carcinoma//J. Urol. 1986. Vol. 136, № 2. P. 422424.
  • Walsh P.C., Partin A.W., Epstein J.I. Cancer control and quality of life following anatomic radical retropubic prostatectomy. Results at 10 years//J. Urol. 1994.Vol. 152, № 5, Pt 2. P. 1831-1836.
  • Mitropoulos D., Kooi S., Rodriguez-Villanueva J., Platsoucas C.D. Charaterization of fresh (uncultured) tumour-inflitrating lymphocytes (TIL) and TIL-derived T cell lines from patients with renal cell carcinoma//Clin. Exp. Immunol. 1994. Vol. 97, № 2. P 321-327.
  • Melder R.J., Whiteside TL., Vujanovic N.L., Hiserodt J.C., Herberman R.B. A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells.//Cancer Res. 1988. Vol. 48, № 12. P. 3461-3469.
  • Topalian S.L., Solomon D., Avis F.P., Chang A.E., Freerksen D.L., Linehan WM., Lotze M.T., Robertson C.N., Seipp C.A., Simon P Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study//J. Clin. Oncol. 1988. Vol.6, № 5. P. 839-853.
  • Slovin S.F, Kelly W.K., Scher H.I. Immunological approaches for the treatment of prostate cancer//Sem. Urol. Oncol. 1998. Vol. 16. P. 53-59.
  • Sanda M.G., Ayyagari S.R., Jaffee E.M., Epstein J.I., Clift S.L., Cohen L.K., Dranoff G., Pardoll D.M., Mulligan R.C., Simons J.W. Demonstration of a rational strategy for human prostate cancer gene therapy//J Urol. 1994. Vol.151, № 3. P 622-628.
  • Xue B.H., Zhang Y., Sosman J.A., Peace D.J. Induction of human cytotoxic T lymphocytes specific for prostatespecific antigen//Prostate. 1997. Vol. 30. P. 73-78.
  • Perambakam S., Xue B.H., Sosman J.A., Peace D.J. Induction of Tc2 cells with specificity for prostate-specific antigen from patients with hormone-refractory prostate cancer//Cancer Immunol Immunother. 2002. Vol. 51. P. 263-270.
  • Terasawa H., Tsang K.Y., Gulley J., Arlen P., Schlom J. Identification and characterization of a human agonist cytotoxic T lymphocyte epitope of human prostate-specific antigen//Clin Cancer Res. 2002. Vol. 8. P. 41-53.
  • Heiser A., Coleman D., Dannull J., Yancey D., Maurice M.A., Lallas C.D., Dahm P., Niedzwiecki D., Gilboa E., Vieweg J. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors.//J Clin Invest. 2002. Vol. 109, № 3. P. 409-417.
  • Correale P, Walmsley K., Zaremba S., Zhu M., Schlom J., Tsang K.Y. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligo-epitope peptide//J Immunol. 1998. Vol. 161, № 6. P. 3186-3194.
  • Harada M., Kobayashi K., Matsueda S., Nakagawa M., Noguchi M., Itoh K. Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24+ prostate cancer patients//Prostate. 2003. Vol. 57. P. 152-159.
  • Eder J.P, Kantoff PW, Roper K., Xu G.X., Bubley G.J., Boyden J., Gritz L., Mazzara G., Oh W.K., Arlen P., Tsang K.Y., Panicali D., Schlom J., Kufe D.W. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer//Clin Cancer Res. 2000. Vol. 6, № 5. P. 1632-1638.
  • Corman J.M., Sercarz E.E., Nanda N.K. Recognition of prostatespecific antigen peptide determinants by human CD4 and CD8 T cells//Clin Exp Immunol. 1998. Vol.114. P. 166-172.
  • Thomas-Kaskel A.K., Zeiser R., Jochim R., Robbel C., Schultze-Seemann W, Waller C.F, Veelken H. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival//Int J Cancer. 2006. Vol. 119, № 10. P. 2428-2434.
  • Perambakam S., Hallmeyer S., Reddy S., Mahmud N., Bressler L., DeChristopher P., Mahmud D., Nunez R., Sosman J.A., Peace D.J. Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide//Cancer Immunol Immunother. 2006. Vol. 55, № 9. P. 1033-1042.
  • Hildenbrand B., Sauer B., Kalis O., Stoll C., Freudenberg M.A., Niedermann G., Giesler J.M., Jüttner E., Peters J.H., Häring B., Leo R., Unger C., Azemar M. Immunotherapy of patients with hormone-refractory prostate carcinoma pretreated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells -a pilot study//Prostate. 2007. Vol. 67, № 5. P.500-508.
  • Schellhammer P.F., Hershberg R.M. Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer//World J Urol. 2005. Vol. 23. P.47-49.
  • Gutman E.B., Sproul E.E., Gutman A.B. Significance of increased phosphatise activity of bone at the site of osteoblastic metastases secondary to carcinoma of the prostate gland//Am J Cancer. 1936. Vol. 28. P. 485.
  • Gutman A.B., Gutman E.B. An «acid» phosphatase occurring in the serum of patients with metastasizing carcinoma of the prostate gland//J Clin Invest. 1938. Vol. 17. P. 473-478.
  • Fong L., Brockstedt D., Benike C., Breen J.K., Strang G., Ruegg C.L., Engleman E.G. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy//J Immunol. 2001. Vol. 167, № 12. P.7150-7156.
  • McNeel D.G., Dunphy E.J., Davies J.G., Frye T.P., Johnson L.E., Staab M.J., Horvath D.L., Straus J., Alberti D., Marnocha R., Liu G., Eickhoff J.C., Wilding G. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer//J. Clin Oncol. 2009. Vol. 27, № 25. P. 4047-4054.
  • Guise T.A. Parathyroid hormone-related protein andbone metastases.//Cancer. 1997. Vol. 80. P. 1572-1580.
  • Francini G., Scardino A., Kosmatopoulos K., Lemonnier F.A., Campoccia G., Sabatino M., Pozz-essere D., Petrioli R., Lozzi L., Neri P., Fanetti G., Cusi M.G., Correale P. High-affinity HLA-A(*) 02.01 peptides from parathyroid hormone-related protein generate in vitro and in vivo antitumor CTL response without autoimmune side effects//J Immunol. 2002. Vol. 169, № 9. P. 4840-4849.
  • Yao A., Harada M., Matsueda S., Ishihara Y., Shomura H., Takao Y., Noguchi M., Matsuoka K., Hara I., Kamidono S., Itoh K. New epitope peptides derived from parathyroid hormone-related protein which have the capacity to induce prostate cancer-reactive cytotoxic T lymphocytes in HLA-A2+ prostate cancer patients//Prostate. 2005. Vol.62, № 3. P. 233-242.
  • Tjoa B.A., Murphy G.P Development of dendritic-cell based prostate cancer vaccine//Immunol Lett. 2000. Vol.74, № 1. P 87-93.
  • Boczkowski D., Nair S.K., Snyder D., Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo//J Exp Med. 1996. Vol. 184, № 2. P. 465-472.
  • Su Z., Dannull J., Yang B.K., Dahm P, Coleman D., Yancey D., Sichi S., Niedzwiecki D., Boczkowski D., Gilboa E., Vieweg J. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer//J Immunol. 2005. Vol. 174, № 6. P 3798-3807.
  • Barrou B., Benoit G., Ouldkaci M., Cussenot O., Salcedo M., Agrawal S., Massicard S., Bercovici N., Ericson M.L., Thiounn N. Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA//Cancer Immunol Immunother. 2004. Vol. 53, № 5. P. 453-460.
  • Murphy G.P., Tjoa B.A., Simmons S.J., Rogers M.K., Kenny G.M., Jarisch J. Higher-dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients//Prostate. 2000. Vol. 43, № 1. P. 59-62.
  • Tjoa B.A., Simmons S.J., Elgamal A., Rogers M., Ragde H., Kenny G.M., Troychak M.J., Boynton A.L., Murphy G.P. Follow-up evaluation of a phase II prostate cancer vaccine trial//Prostate. 1999. Vol. 40, № 2. P. 125-129.
  • Fuessel S., Meye A., Schmitz M., Zastrow S., Linné C., Richter K., Löbel B., Hakenberg O.W, Hoelig K., Rieber E.P, Wirth M.P Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial//Prostate. 2006. Vol. 66, № 8. P. 811-812.
  • Prostate cancer vaccine-Northwest Biotherapeutics: CaPVax, DC1/HRPC, DCVax-Prostate//BioDrugs. 2002. Vol. 16, № 3. P. 226-227.
  • Small E.J., Fratesi P., Reese D.M., Strang G., Laus R., Peshwa M.V., Valone FH. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells//J Clin Oncol. 2000. Vol. 18, № 23. P. 3894-3903.
  • Burch P.A., Croghan G.A., Gastineau D.A., Jones L.A., Kaur J.S., Kylstra J.W, Richardson R.L., Valone FH., Vuk-Pavlovic S. Immunotherapy (APC8015, Provenge®) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: A phase 2 trial//Prostate. 2004. Vol. 60, № 3. P. 197-204.
  • Small E.J., Schellhammer P.F., Higano C.S., Redfern C.H., Nemunaitis J.J., Valone F.H., Verjee S.S., Jones L.A., Hershberg R.M. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer//J Clin Oncol. 2006. Vol. 24, № 19. P. 3089-3094.
  • Higano C.S., Schellhammer P.F., Small E.J., Burch P.A., Nemunaitis J., Yuh L., Provost N., Frohlich M.W. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer//Cancer. 2009. Vol. 115, № 16. P. 3670-3679.
Еще
Статья
SciUp 2024 © 2024 ©